Closing the Gaps in HAE Management: Addressing HAE Management Challenges for Adolescents

This webinar was funded by KalVista Pharmaceuticals, part of the Chiesi Group, and is intended for healthcare professionals only.

Disclaimer: The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of KalVista or EMJ.

The speakers received honoraria for participating in this recording.

This webinar is focused on improving the management of hereditary angioedema (HAE) in adolescents. It brings together an international panel of allergy and immunology experts to discuss how “control” is defined, the updated 2026 HAE guidelines, and the challenges for adolescents with HAE.

1. University Hospital of Padua, Italy
2. Immunology & Allergy, Cardiff and Vale University Health Board, UK
3. Hospital Universitari Vall d’Hebron, Barcelona, Spain
4. Charité – Universitätsmedizin Berlin, Institute of Allergology IFA, Berlin, Germany 

Disclosures: 

Cancian has received support from ADARx, Argo Biopharma, Chiesi, Intellia, Neopharmed Gentili, KalVista Pharmaceuticals, BioCryst, CSL Behring, Otsuka, Pharvaris, and Takeda.

Carne has received research grants, honoraria and meeting support from Biocryst, CSL Behring, Grifols, KalVista Pharmaceuticals, LFB, Novartis, Otsuka, Pfizer, Pharming, Kedrion, and Takeda.

Guilarte has received grants/honoraria, meeting/travel support from, served on advisory boards, and/or served on advisory boards for BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis, Pharming, Pharvaris, and Takeda.

Magerl has received honoraria, consulted for, served on advisory boards, and/or medical writing support from Adivo, Astria, BioCryst, CSL Behring, Forum Sanitas, GA²len, Hallema, KalVista Pharmaceuticals, Lilly, Octapharma, Otsuka, Pharvaris, Streamed Up, Takeda.